- Company launches first Zerenia™ medical cannabis clinic outside of Colombia , exporting proven clinic model via strategic partnership with Lima -based Clinica Montesur
- Clinica Montesur is a specialized medical clinic with over 90 doctors covering 19 specialties and 11,000 patient transactions annually; its clinic is centrally located in Lima, Peru , a city of 10 million people or a third of the country's total population
- Partnership combines Khiron's unique medical cannabis expertise, including the Company's real-world evidence, medical education, best practices and systems, with Clinica Montesur's patient base, clinical infrastructure and medical staff
- In Q1 2021, Khiron's medical cannabis sales in Peru increased by over 175% compared to total sales in 2020
- Zerenia™ is the category leader in medical cannabis sales in Colombia , with over 20,000 filled prescriptions and over 8,000 individual patients to date, 50% patient retention, and average 90% gross margins
- The new Zerenia location brings Khiron's total clinic count to 11 across Latin America
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe today announces the launch of its first Zerenia TM clinic outside of Colombia in Lima, Peru . Following the success of the Company's clinic strategy in Colombia the new clinic has been established as a strategic partnership between Khiron and Clinica Montesur, a specialized medical provider in Lima with over 90 physicians and more than 11,000 patient transactions annually.
Alvaro Torres , CEO and Director comments, "I am pleased to announce the first expansion of our Zerenia brand beyond Colombia . Knowing that prescription rates at our Zerenia clinics are 14 times higher than those of our external clinic partners, we are excited to bring a proven marketing, sales, and distribution model to a market of over ten million people. To date, our Zerenia clinics have played a vital role in not only introducing patients to Khiron products, but also in developing an exceptional patient experience and growing base of returning patients. As we continue to develop our unique, service-oriented platform, we are proud to introduce Zerenia to the Peruvian market, where initial reception to our products has been strong since sales began late last year."
With over 30 years of experience in Peru , Clinica Montesur is dedicated to high quality care across 19 areas of specialization, including oncology, dermatology, ophthalmology, and psychology. As part of the strategic partnership, Clinica Montesur will provide clinic infrastructure, including its medical facility, clinic permits, systems, and medical staff, among others. The partnership will leverage Khiron's unique Zerenia TM medical cannabis model, including the Company's medical cannabis education platform, real-world evidence, and standard operating procedures. Patients of the clinic will be able to fill prescriptions for High THC and Low THC (CBD) medical cannabis at ten Farmacia Universal S.A.C. locations throughout Lima , as previously announced by the Company.
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe . Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia , Peru , Germany and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres , together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com . The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2021/10/c1216.html